Document:

AMENDEMENT TO THE ASSIGNMENT AGREEMENT BETWEEN

MEDICAL DEVICE INTERNATIONAL LIMTED, ASSIGNOR

AND LIFE CARE MEDICAL DEVICES, ASSIGNEE

 

The duly executed assignment of intellectual
property agreement of International Patent Application No. PCT/IB2010/000797 from Medical Device International Limited, Assignor
to Life Care Medical Devices Limited, Assignee is hereby amended to include the following terms and conditions:

 

Life Care Medical Devices Limited shall
pay to Medical Device International Limited 2% of net sales it receives as a result of the sale of product resulting from the reduction
in practice of the aforementioned provisional patent.

 

Life Care Medical Devices shall supply
to Medical Device International Limited a signed report of net sales on a monthly basis no longer than 7 days from the end of the
month.

 

Remuneration in the amount of 2% of the
total royalty revenue related to the assigned intellectual property shall be paid to Medical Device International Limited by the
14th calendar day of the month following.

 

Remuneration to Medical Device International
Limited shall commence no later than January 2011 and shall not be any less than $5,000/month beginning January 2011.

 

	AGREED:	 	 
	 	 	 
	ASSIGNOR:	 	ASSIGNEE:
	 	 	 
	/s/	 	/s/
	Medical Device International Limited	 	Life Care Medical Devices Limited
	By:  Arthur Malvett	 	By:  Glenn S. Foley
	Managing Director	 	Managing Director
	Date:  August 11, 2010	 	Date:ASSIGNMENT

 

WHEREAS, MEDICAL DEVICE
INTERNATIONAL LIMITED, a Limited liability company, of Hong Kong, having a principal place of business at 210 Nathan Road, Jordan,
Kowloon Hong Kong (hereinafter referred to as ASSIGNEE) desires to acquire all right, title, and interest in and to the following
identified PCT provisional patent and to the invention of the following identified PCT provisional patent:

 

Patrick Marandah Co., Intellectual Property Attorneys, Malaysia

Internal document number: 7798MYl/PM/IAN/tam, Bandage based
pain control through the delivery of electric impulses to the body

 

WHEREAS, LEAP MEDICAL,
a Limited Liability Company, of North Carolina/United States of America, having a principal place of business at 335 Gorrell Street,
Greensboro, North Carolina, 27406, (hereinafter referred to as ASSIGNOR), is the owner of record of the aforementioned PCT provisional
patent.

 

NOW, THEREFORE, in exchange
for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby assigns, and transfers unto ASSIGNEE:

 

The entire right, title and interest
in the above-identified Patent Properties and in the corresponding inventions and in all subsequent divisions and continuations
of said Patent Properties, or reissues or extensions thereof and in all patents issuing thereon in the United States or foreign
countries, and in all corresponding patent applications filed in countries foreign to the United States, and in all patents issuing
thereon in said foreign countries.

 

The right to file foreign patent
applications on said invention in its own name, wherever such right may be legally exercised, including the right to claim the
benefits of the International Convention for such applications.

 

NOW THEREFORE, it is
understood that ASSIGNOR shall receive from ASSIGNEE royalty payments equal to 50% of the net revenue collected by ASSIGNEE from
the commercial sale of the product resulting from reduction to practice of the assigned provisional patent and improvements or
additional patents issued as a result of improvements or modifications to the aforementioned patent and all referenced property
outlined above. Payment shall be made on a calendar quarterly basis, within 45 days of the end of the calendar quarter, with payments
beginning no later than May 15, 2011 and totaling no less than $10,000 per calendar quarter.

 

ASSIGNEE will pay all
patent expenses and patent maintenance fees as required to maintain the above-identified Patent Properties.

 

    	 

    	 

    

 

ASSIGNEE will provide an annual report,
to the ASSIGNOR, due each February and certified by a reputable accounting firm, verifying total yearly commercial sales of the
referenced patent. ASSIGNOR shall have the right personally, or through an agent, but at its own expense, to examine the ASSIGNEE'S
books for the purpose of determining its gross sales. Such examination may be made at any time designated by the ASSIGNOR.

 

ASSIGNEE shall be responsible for any securing
legal representation and any resulting legal fees necessary to defend or prosecute protection of above referenced pending or issued
patent.

 

ASSIGNEE agrees to indemnify ASSIGNOR from
any product liability or consequential damages that may result from manufacture and commercialization of aforementioned patent
and that said indemnification survives termination of any agreement.

 

ASSIGNEE agrees that in the event that
they cease to do business, become insolvent or declares bankruptcy that all rights of the aforementioned patent are returned to
the ASSIGNOR without any encumbrances of assets.

 

This Agreement shall not be terminated
by any dissolution of the ASSIGNOR'S or ASSIGNEE'S Corporation resulting from either merger or consolidation in which the Corporation
is not the consolidated or surviving corporation or a transfer of all or substantially all of the assets of the Corporation. In
such event, the rights, benefits and obligations herein shall automatically be assigned to the surviving or resulting corporation
or to the transferee of the assets.

 

This Agreement will be binding upon ASSIGNOR'S
heirs, executors, administrators and other legal representatives and will be for the benefit of the any, its successors, and its
assigns. If one or more of the provisions in this Agreement is deemed void by law, then the remaining provisions will continue
in fill force and effect.

 

ASSIGNOR hereby authorizes and requests
the Commissioner for Patents of the United States, and such Patent Office officials in foreign countries as are duly authorized
by their patent laws to issue patents, to issue all letters patent on said invention to ASSIGNEE.

 

ASSIGNOR agrees to execute all instruments
and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention,
for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefore.

 

Any controversy or claim arising out of
or relating to this Agreement, or the breach thereof shall be settled by arbitration before three arbitrators in the City of Greensboro,
Guilford County, North Carolina, in accordance with the governing rules of the American Arbitration Association. Judgment upon
any award rendered by the arbitrators may be entered in any court of competent jurisdiction.

 

    	 

    	 

    

 

Any additional required agreements, documents,
or the like shall be executed in a timely manner following execution of this agreement.

 

This assignment is effective
the 6 day of, March, 2010.

 

Signed this 6 day of
March, 2010 on behalf of ASSIGNEE.

 

	 	Medical Device International Limited A Hong Kong company
	 	 
	 	Signature:	/s/
	 	Name:	Glenn S. Foley
	 	Title:	MANAGING DIRECTOR

 

Accepted this 5th day of ____March ___________,
2010 on behalf of ASSIGNOR.

 

	 	Leap Medical, LLC
	 	A North Carolina Limited Liability Company
	 	 
	 	Signature:	/s/
	 	 
	 	Name: Richard Kent Riddle
	 	Title: MANAGING DIRECTORASSIGNMENT

 

THIS ASSIGNMENT,
effective this 5th day of October, 2010 between Medical Device International Limited having its principal place
at Unit 1001 Fourseas Building, 208-212 Nathan Road, Jordan Kowloon, Hong Kong “(hereinafter referred to as “the
Assignor(s)”) and Life Care Medical Devices Limited having its principal place at Unit 2508A, Bank of America Tower,
Central Hong Kong (hereinafter referred to as “the Assignee(s)”);

 

WHEREAS THE ASSIGNOR
is the owner of International Patent (PCT No. Pending) filed with Patrick Mirandah Co., Intellectual Property Attorneys,
Kuala Lumpur, Malaysia, under Internal Document number: 7798MYl/PM/IAN/tam Bandage based pain control through the delivery
of electric impulses to the body (hereinafter referred to as the “Patent Rights”);

 

WHEREAS THE ASSIGNEE
is desirous of acquiring the entire right, title and interest in, to and under the said Patent Rights and the inventions covered
thereby;

 

NOW, THEREFORE,
for and in consideration of United States Dollar One only (USDl.OO) and other good and valuable consideration paid by the ASSIGNEE
to the said ASSIGNOR, the receipt and sufficiency of which are hereby acknowledge by the said ASSIGNOR, the said ASSIGNOR has sold,
assigned, transferred and conveyed to the said ASSIGNEE, its successors, legal representatives and assigns, the entire right, title
and interest in and the said Patent Rights including all patents that may issue thereof and the inventions covered thereby, as
fully and entirely as the same would have been held and enjoyed by the said ASSIGNOR if this assignment and sale has not been made,
to the end of the terms or terms for which the said Patent Rights are granted.

 

    	1

    	 

    

 

Patent Rights are granted.

 

IN WITNESS WHEREOF
the said parties hereto have caused these presents to be duly executed by their respective officers duly authorized in their behalf
and shall be deemed effective from this date and year hereinbefore written.

 

	Medical Device International Limited	 	 
	 	 	 
	SIGNED AND DELIVERED by	)	 
	 	)	 
	In the presence of:-	)	/s/
	 	 	Name:  ARTHUR R. MALVETT
	 	 	Designation:  DIRECTOR
	 	 	 
	 	 	 
	Name of Witness:	 	 
	Designation:	 	 
	 	 	 
	Life Care Medical Devices Limited	 	 
	SIGNED AND DELIVERED by	)	 
	 	)	 
	In the presence of:-	)	/s/
	 	 	Name: GLENN S. FOLEY
	 	 	Designation:  Chairman
	 	 	 
	 	 	 
	Name of Witness: Designation:	 	 

 

    	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]